You are here

  We have evaluated blood viscosity parameters in 20 men suffering from coronary heart disease (CHD) and in 15 control subjects. Whole bloodviscosity at a standardized haematocrit of 45% was significantly increased in the CHD-patients, both at low (p less than 0.001) and high (p less than0.05)...
Type: Abstracts
  It is known from previous studies that hemorheological parameters are altered in patients with essential hypertension. The hemorheological and hemodynamical effects of doxazosin, a selective alpha-1-adrenoreceptor blocker agent, was examined in twenty patients (mean age: 54+/-10 years) with...
Type: Abstracts
  Propofol has previously been found to decrease hematocrit values. Because hematocrit is an important determinant of blood viscosity, lowerhematocrits may cause a decrease in blood viscosity, improving blood flow and oxygen delivery. This phenomenon may be beneficial in certain intraoperative...
Type: Abstracts
  Elevated plasma fibrinogen level is known to progress atherosclerosis and to be one of the risk factors for the occurrence of cardiovascular diseases. The objective of this study is to evaluate the changes in plasma fibrinogen level and blood rheology in patients with type II...
Type: Abstracts
  Hemorheological factors play an important role in the pathogenesis of different cardiovascular diseases. The hemorheological and hemodynamic parameters in essential hypertension and their possible modification by antihypertensive treatment were examined in the following two studies. In the first...
Type: Abstracts
  Blood viscosity (eta B) at shear rates 10 and 100s-1, plasma viscosity (eta P), hematocrit (Hct), and whole blood cholesterol (Chol) were measured in50 patients with a history of myocardial infarction or unstable angina pectoris. Erythrocyte morphology was also studied by scanning electron...
Type: Abstracts
  Pravastatin sodium, a newly developed potent synthesis inhibitor of HMG-CoA (beta-hydroxy-beta-methylglutaryl-cocarboxylase-A) reductase(Sankyo Co., Ltd., Japan) was medicated, 10 approximately 15 mg/day (mean: 11.1 mg/day) for 10.2 weeks in mean, in 14 patients with primaryhyperlipoproteinemia...
Type: Abstracts

Stay Connected